150 related articles for article (PubMed ID: 38049855)
1. Non-invasive biomarkers for early diagnosis of pancreatic cancer risk: metabolite genomewide association study based on the KCPS-II cohort.
Han Y; Jung KJ; Kim U; Jeon CI; Lee K; Jee SH
J Transl Med; 2023 Dec; 21(1):878. PubMed ID: 38049855
[TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis.
Luo X; Liu J; Wang H; Lu H
Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036
[TBL] [Abstract][Full Text] [Related]
4. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.
Ritchie SA; Akita H; Takemasa I; Eguchi H; Pastural E; Nagano H; Monden M; Doki Y; Mori M; Jin W; Sajobi TT; Jayasinghe D; Chitou B; Yamazaki Y; White T; Goodenowe DB
BMC Cancer; 2013 Sep; 13():416. PubMed ID: 24024929
[TBL] [Abstract][Full Text] [Related]
5. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer.
Xiong Y; Shi C; Zhong F; Liu X; Yang P
Clin Chim Acta; 2020 Jul; 506():214-221. PubMed ID: 32243985
[TBL] [Abstract][Full Text] [Related]
6. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
Pang Y; Holmes MV; Chen Z; Kartsonaki C
J Gastroenterol Hepatol; 2019 Feb; 34(2):330-345. PubMed ID: 30550622
[TBL] [Abstract][Full Text] [Related]
7. Metabolomics study reveals systematic metabolic dysregulation and early detection markers associated with incident pancreatic cancer.
Wang S; Li M; Yan L; He M; Lin H; Xu Y; Wan Q; Qin G; Chen G; Xu M; Wang G; Qin Y; Luo Z; Tang X; Wang T; Zhao Z; Xu Y; Chen Y; Huo Y; Hu R; Ye Z; Dai M; Shi L; Gao Z; Su Q; Mu Y; Zhao J; Chen L; Zeng T; Yu X; Li Q; Shen F; Chen L; Zhang Y; Wang Y; Deng H; Liu C; Wu S; Yang T; Li D; Ning G; Wu T; Wang W; Bi Y; Lu J;
Int J Cancer; 2022 Apr; 150(7):1091-1100. PubMed ID: 34792202
[TBL] [Abstract][Full Text] [Related]
8. Metabolic changes preceding bladder cancer occurrence among Korean men: a nested case-control study from the KCPS-II cohort.
Han Y; Kim U; Jung KJ; Lee JY; Lee K; Shin SY; Kimm H; Jee SH
Cancer Metab; 2023 Dec; 11(1):23. PubMed ID: 38053135
[TBL] [Abstract][Full Text] [Related]
9. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics.
Hirata Y; Kobayashi T; Nishiumi S; Yamanaka K; Nakagawa T; Fujigaki S; Iemoto T; Kobayashi M; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Yamada T; Honda K; Azuma T; Yoshida M
Clin Chim Acta; 2017 May; 468():98-104. PubMed ID: 28215548
[TBL] [Abstract][Full Text] [Related]
10. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
11. Prospective metabolomics study identifies potential novel blood metabolites associated with pancreatic cancer risk.
Shu X; Zheng W; Yu D; Li HL; Lan Q; Yang G; Cai H; Ma X; Rothman N; Gao YT; Jia W; Xiang YB; Shu XO
Int J Cancer; 2018 Nov; 143(9):2161-2167. PubMed ID: 29717485
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters.
Urayama S
World J Gastroenterol; 2015 Feb; 21(6):1707-17. PubMed ID: 25684935
[TBL] [Abstract][Full Text] [Related]
13. Prediction model for pancreatic cancer risk in the general Japanese population.
Nakatochi M; Lin Y; Ito H; Hara K; Kinoshita F; Kobayashi Y; Ishii H; Ozaka M; Sasaki T; Sasahira N; Morimoto M; Kobayashi S; Ueno M; Ohkawa S; Egawa N; Kuruma S; Mori M; Nakao H; Wang C; Nishiyama T; Kawaguchi T; Takahashi M; Matsuda F; Kikuchi S; Matsuo K
PLoS One; 2018; 13(9):e0203386. PubMed ID: 30192808
[TBL] [Abstract][Full Text] [Related]
14. A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival.
Willis JA; Olson SH; Orlow I; Mukherjee S; McWilliams RR; Kurtz RC; Klein RJ
Clin Cancer Res; 2012 Jul; 18(14):3942-51. PubMed ID: 22665904
[TBL] [Abstract][Full Text] [Related]
15. Development of a Correlative Strategy To Discover Colorectal Tumor Tissue Derived Metabolite Biomarkers in Plasma Using Untargeted Metabolomics.
Wang Z; Cui B; Zhang F; Yang Y; Shen X; Li Z; Zhao W; Zhang Y; Deng K; Rong Z; Yang K; Yu X; Li K; Han P; Zhu ZJ
Anal Chem; 2019 Feb; 91(3):2401-2408. PubMed ID: 30580524
[TBL] [Abstract][Full Text] [Related]
16. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
[TBL] [Abstract][Full Text] [Related]
17. Validation of genome-wide association study-identified single nucleotide polymorphisms in a case-control study of pancreatic cancer from Taiwan.
Shan YS; Chen LT; Wu JS; Chang YF; Lee CT; Wu CH; Chiang NJ; Huang HE; Yen CJ; Chao YJ; Tsai HJ; Chen CY; Kang JW; Kuo CF; Tsai CR; Weng YL; Yang HC; Liu HC; Chang JS
J Biomed Sci; 2020 May; 27(1):69. PubMed ID: 32456644
[TBL] [Abstract][Full Text] [Related]
18. Metabolomics Profiles of Hepatocellular Carcinoma in a Korean Prospective Cohort: The Korean Cancer Prevention Study-II.
Jee SH; Kim M; Kim M; Yoo HJ; Kim H; Jung KJ; Hong S; Lee JH
Cancer Prev Res (Phila); 2018 May; 11(5):303-312. PubMed ID: 29500188
[TBL] [Abstract][Full Text] [Related]
19. LC-MS/MS platform-based serum untargeted screening reveals the diagnostic biomarker panel and molecular mechanism of breast cancer.
Gong S; Wang Q; Huang J; Huang R; Chen S; Cheng X; Liu L; Dai X; Zhong Y; Fan C; Liao Z
Methods; 2024 Feb; 222():100-111. PubMed ID: 38228196
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
